How Will the Market React to Maravai Lifesciences Holdings Inc (MRVI) Stock Getting a Bearish Rating

Maravai Lifesciences Holdings Inc (MRVI) stock is lower by 2.43% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Maravai Lifesciences Holdings Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on MRVI!

See Full MRVI Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With MRVI Stock Today?

Maravai Lifesciences Holdings Inc (MRVI) stock has risen 2.35% while the S&P 500 is down -0.04% as of 10:43 AM on Friday, Dec 1. MRVI has gained $0.12 from the previous closing price of $5.10 on volume of 242,123 shares. Over the past year the S&P 500 is up 11.91% while MRVI is down -64.92%. MRVI earned $0.47 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 11.06. To screen for more stocks like Maravai Lifesciences Holdings Inc click here.

More About Maravai Lifesciences Holdings Inc

Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples. Click Here to get the full Stock Report for Maravai Lifesciences Holdings Inc stock.